Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93(21):1633–7. Article PubMed CAS Google Scholar Li X, You R, Wang X, Liu C, Xu Z, Zhou J, et al. Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation...
Experiences of BRCA1/2 Gene Mutation-Positive Women With Cancer in Communicating Genetic Risk to Their RelativesBRCACancerExperiencesFamilyGeneticRisk communicationBackgroundSeven, MemnunShah, Lisa L.Daack-Hirsch, SandraYazici, HulyaUniv Massachusetts Coll Nursing 230 Skinner Hall 651 N Pleasant St ...
Learning You Have the BRCA1 or BRCA2 Gene Mutation I didn’t find out I had the BRCA1 gene mutation until 2 weeks after I was diagnosed, one week after I had already had a double mastectomy. Even though my breast cancer was stage 1, it was also “triple negative,” or the most ag...
The investigational PARP inhibitor veliparib (AbbVie) has shown what investigators say is "promising and encouraging" activity in women with treatment-resistant ovarian cancer who carry aBRCA1orBRCA2mutation. In a phase 2 study of 50 women withBRCAgene mutations, treatment with veliparib resulted in...
Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer 来自 国家科技图书文献中心 喜欢 0 阅读量: 24 作者:Kadouri,Luna,Hamburger,Tamar,Peretz,Halpern,Naama,Sonnenblick,Amir,Uziely,Beatrice,Divinsky,Luba,Goldberg,Yael ...
Specific downstream targets of STAT3 can clarify the phenotypic changes in breast cancer cells following STAT3 mutation and/or overexpression. When STAT3 is activated to promote signaling, breast cancer cells acquire the basic abilities of tumor cells, such as proliferation, invasion, metastasis, immune...
Exclusion criteria included: treatment with hormonal therapy within three months of randomization; known mutation carrier status for the breast cancer genes BRCA1 and BRCA2. The original MAP.3 design involved randomization of 5100 eligible women to three arms: exemestane 25 mg/day, exemestane 25 mg...
2, 366–375 (2012). CAS PubMed PubMed Central Google Scholar Popova, T. et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res. 72, 5454–5462 (2012). CAS PubMed Google Scholar Ock, C. Y. et al. ...
p63 isoforms in triple-negative breast cancer: DeltaNp63 associates with the basal phenotype whereas TAp63 associates with androgen receptor, lack of BRCA mutation, PTEN and improved survival. Virchows Arch. 2018;472(3):351–9. Article PubMed CAS Google Scholar Di Franco S, Sala G, Todaro ...
associated with the presence of a TP53 mutation (P ¼ 5 Â 10 À 2, Mann–Whitney U-test). The homologous recombination deficiency, measured by computing a BRCAness score as previously reported37 (Methods), was increasing from RNA groups A through D (Supplementary Fig. 2g). The ERBB...